SABRA HEALTH CARE REIT INC (SBRA)
Real Estate · healthcare REITs · NASDAQ
Sabra Health Care REIT is a specialized real estate investment trust focused on the ownership and management of skilled nursing facilities and senior housing communities.
What SABRA HEALTH CARE REIT INC does
Sabra Health Care REIT, Inc. is a real estate investment trust that owns and invests in a portfolio of real estate assets within the healthcare sector. The company primarily focuses on skilled nursing and transitional care facilities, as well as senior housing communities. It operates through property investments and manages a portfolio of healthcare-related properties across the United States.
Themes: healthcare real estate, skilled nursing facilities, senior housing, REITs
Fundamentals
- Price$20.47 as of 2026-08-24 close
- Market cap$5.2B as of 2026-08-24
- 1-year return+4.7% 2025-08-22 close $19.55 → 2026-08-24 close $20.47
- P/E78.79 as of 2026-08-24
- Net margin+7.6% as of 2026-08-24
- Gross margin+63.6% as of 2026-08-24
- ROE+2.3% as of 2026-08-24
- Debt / equity0.95 as of 2026-08-24
- Revenue growth (YoY)+17.3% as of 2026-08-24
- Revenue CAGR (3y)+7.4% SEC XBRL
- Beta0.07 as of 2026-08-24
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +8.3%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How SBRA compares in its sector
- price-to-earnings ratiotop 25% 122 covered Real Estate peers, as of 2026-08-24
- net profit marginmiddle range 161 covered Real Estate peers, as of 2026-08-24
- operating marginmiddle range 161 covered Real Estate peers, as of 2026-08-24
- gross marginmiddle range 156 covered Real Estate peers, as of 2026-08-24
- return on equitymiddle range 162 covered Real Estate peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 155 covered Real Estate peers
- indicated dividend yieldtop 25% 138 covered Real Estate peers, as of 2026-08-24
Position among covered Real Estate companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
SBRA is not currently in any published Top 10 list. Its scores are below.
Long-term score
46.4 #637 of 987 scored · #60 of 84 in Real Estate
Capital return 71st (consecutive years of dividend increases 5 years) and growth 71st (revenue growth year over year 17.3%, 3-year revenue CAGR 7.4%); weakest is profitability (12th, return on equity 2.3%, operating margin 4.5%).
Short-term score
42.3 #1286 of 1,704 scored · #62 of 94 in Real Estate
Trend 58th: a "golden cross" — its 50-day average is above its 200-day; setup 54th: no fresh 20-day breakout up or down; weakest is volume and participation 7th: trading volume is about normal versus its 30-day average.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Exceeded at least one reported measure. In FY2025, SBRA's dividend exceeded at least one reported measure of what it earned or generated (earnings payout 186%, operating-cash-flow payout 83%). A payout above 100% in one year is not necessarily unsustainable, but it is not fully covered by that measure.
- Earnings payout186% dividends / net income
- Operating-cash-flow payout83% dividends / operating cash flow — capital spending was not reported, so this does not subtract it
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How SABRA HEALTH CARE REIT INC looks technically
SABRA HEALTH CARE REIT INC (SBRA) is trading 3.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 296 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 20 trading days ago.
Trend
9
| Distance from the 200-day | it is trading 3.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +3.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $20.09 | $20.09 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $19.73 | $19.73 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes below 19.71. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 296 trading days ago — a "golden cross", a bullish long-term signal | 296 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 3.3% above | +3.3% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 14.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30) | 48.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($19.71 to $21.59) — its "stochastic" reading is 36 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 36.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 15 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $22.77 | $22.77 |
|---|---|---|
| From the 52-week high | it is 10.5% below its 52-week high (its highest price of the past year) | -10.4% |
| Above the 52-week low | it is 18.8% above its 52-week low (its lowest price of the past year) | +18.8% |
| Below the 52-week high | it is 10.5% below its highest point of the past year | 10.4% |
| Since a 20-day breakout | it made a new 20-day high about 20 trading days ago | 20 sessions |
| Since a 55-day breakout | it made a new 55-day high about 20 trading days ago | 20 sessions |
| All-time high | its highest closing price on record is $72.39 (set on 2002-04-26) | $72.39 |
| Given back of the 52-week move | over the past year its closes ranged ($17.23 to $22.39), and it has given back roughly a third of its rise from last year’s low — 39% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $19.04 to $19.20. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 38.8% |
| From the all-time high | it is 71.8% below its all-time high | -71.8% |
| Nearest price level | it is trading 1.1% below a resistance level at $20.62 — a price it turned at three times since 2026-02-17, most recently on 2026-07-07. Since 2024-08-21 it has 9 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.1% |
| All-time low | its lowest closing price on record is $0.33 (set on 2003-04-14) | $0.33 |
| Above the all-time low | it is 6078.8% above its all-time low | +6,079% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 58th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5038 between its high and its low — about 2.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5038 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $19.46 and $22.22 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $19.46 – $20.84 – $22.22 |
| Typical daily range (% of price) | its price moves about 2.5% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.5% |
| Stretch from the 200-day average | it is trading 1.3 daily ranges above its 200-day average price (3.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.53× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.6% since the prior reading | -0.6% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
|---|---|---|
| Since a bearish engulfing | today it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | today |
Price gaps
1
| Gap at the open | it opened on 2026-08-21 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.4% |
|---|
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -0.73% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 9.8 percentage points (the stock lost 7.5% while the market gained 2.3%) | -9.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 4.6 percentage points (the stock lost 1.5% while the market gained 3.1%) | -4.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 8.8 percentage points (the stock gained 2.3% while the market gained 11.1%) | -8.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 16.6 percentage points (the stock gained 3.9% while the market gained 20.5%) | -16.6% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 4.5% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.5% of the share price, which is taken to mean a barrier that gives way easily. | +4.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 3% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $19.89 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | +2.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-03 (its 10-Q), so the typical buyer over that stretch is under water. That average is $20.52 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | -0.7% |
Price levels it has turned at before
SBRA last closed at $20.39 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $20.62 | Resistance | 1.1% above the last close | turned there three times · 2026-02-17 to 2026-07-07 |
| $19.86 | Support | 2.6% below the last close | turned there six times · 2024-11-01 to 2026-08-14 |
| $21.07 | Resistance | 3.3% above the last close | turned there twice · 2026-02-27 to 2026-03-16 |
| $19.34 | Support | 5.1% below the last close | turned there 10 times · 2024-09-18 to 2026-07-15 |
| $18.80 | Support | 7.8% below the last close | turned there six times · 2025-06-24 to 2025-12-11 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes below $19.71.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $20.74 and $22.41 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · trendless / choppy (low ADX) · lagging the market · Printed a bearish engulfing pair · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.31 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$22.57 range $19.00 – $25.00; median $23.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SBRA
- Consensus EPS estimate$0.1667 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Concentration in the healthcare property sector, particularly skilled nursing and senior housing, increases vulnerability to industry-specific downturns and regulatory changes.","Dependence of tenants and operators on government reimbursement programs and potential risks related to their insolvency or bankruptcy.","Exposure to increased labor costs and shortages affecting tenants and managed communities."]
What changed in the latest 10-Q
AI-assisted comparison of SBRA's 10-Q filed 2026-04-29 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-04-29) references '2025 Annual Report on Form 10-K' while older filing (2025-11-05) references '2024 Annual Report on Form 10-K'
- Newer filing (2026-04-29) includes section header 'Medicare Reimbursement Rates' while older filing (2025-11-05) has 'Skilled Nursing Facility Reimbursement Rates'
- Newer filing (2026-04-29) describes acquisitions during 'three months ended March 31, 2026' of three Senior Housing - Managed communities and one skilled nursing/transitional care facility for $96.1 million
- Newer filing (2026-04-29) states portfolio as of March 31, 2026 consisted of 361 real estate properties held for investment, three assets held for sale, 13 investments in loans receivable, five preferred equity investments and two investments in unconsolidated joint ventures
- Newer filing (2026-04-29) states portfolio as of March 31, 2025 consisted of 364 real estate properties held for investment, 15 investments in loans receivable, four preferred equity investments and two investments in unconsolidated joint ventures
- Removed:
- Older filing (2025-11-05) describes acquisitions during 'nine months ended September 30, 2025' of seven Senior Housing - Managed communities and 24 units plus purchase of operations of four Senior Housing - Managed communities for aggregate $302.8 million
- Older filing (2025-11-05) includes 'Dispositions' section describing sale of seven skilled nursing/transitional care facilities and one behavioral health facility for $42.9 million net with $5.5 million net gain
- Older filing (2025-11-05) includes 'Senior Unsecured Notes' section describing July 31, 2025 redemption of $500.0 million of 5.125% senior unsecured notes due 2026
- Older filing (2025-11-05) includes 'Term Loan Credit Facility' section describing July 30, 2025 entry into Term Loan Credit Agreement
- Older filing (2025-11-05) includes 'At-The-Market Common Stock Offering Program' section describing August 5, 2025 establishment of ATM Program for up to $750.0 million
- Older filing (2025-11-05) UPREIT structure description states 'of which we are the sole general partner and a wholly owned subsidiary of ours is currently the only limited partner'
- Reworded:
- Newer filing (2026-04-29) states 'Increases in operating expenses, inflation and increased volatility' while older filing (2025-11-05) states 'Increases in interest rates and operating expenses, inflation and increased volatility'
- Newer filing (2026-04-29) UPREIT structure states 'We are the sole general partner of the Operating Partnership and we and one of our wholly owned subsidiaries are the sole limited partners' while older filing (2025-11-05) states different partnership structure language
- Notes:
- Newer filing text appears truncated at end ('The results of operations presented are n'), limiting full comparison of Results of Operations section
- Older filing text also appears truncated at end, limiting complete comparison of Critical Accounting Policies section
- The two filings cover different reporting periods (Q1 2026 vs. nine months ended September 30, 2025), which accounts for many structural and content differences
Risk Factors
- Added:
- Removed specific reference to 'COVID-19' from pandemic/epidemic risk factor (newer filing filed 2026-04-29)
- Removed:
- Removed bullet point regarding 'the potential variability of our reported rental and related revenues as a result of Accounting Standards Update (ASU) 2016-02, Leases, as amended by subsequent ASUs' (older filing filed 2025-11-05)
- Removed 'such as COVID-19' from pandemic/epidemic risk factor (older filing filed 2025-11-05)
- Reworded:
- Reordered first two risk factors: 'increases in market interest rates and inflation' moved to first position, 'pandemics or epidemics' moved to second position (older filing had 'increased labor costs and labor shortages' first); newer filing filed 2026-04-29
- Updated reference from 'Annual Report on Form 10-K for the year ended December 31, 2024 (our "2024 Annual Report on Form 10-K")' to 'Annual Report on Form 10-K for the year ended December 31, 2025 (our "2025 Annual Report on Form 10-K")'; newer filing filed 2026-04-29
- Updated 'Item 1A. Risk Factors' page reference from 42 to 35; newer filing filed 2026-04-29
- Updated 'Item 5. Other Information' page reference from 42 to 35; newer filing filed 2026-04-29
- Updated 'Item 6. Exhibits' page reference from 42 to 35; newer filing filed 2026-04-29
- Updated 'Signatures' page reference from 44 to 37; newer filing filed 2026-04-29
- Notes:
- The consolidated balance sheet dates differ between filings (March 31, 2026 vs. September 30, 2025 comparison periods), reflecting different quarterly reporting dates
- The text appears truncated at the end of both filings provided, limiting complete assessment of all Risk Factors content
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for SBRA — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
SBRA had 24,536,972 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SBRA had 9.60% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.41 days to cover at the same settlement.
- Reported short interest (shares) 24,536,972
- Short interest (% of shares outstanding) 9.60%
- Prior settlement (shares) 24,987,251
- Reported change -1.8%
- Days to cover (reported) 7.41
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Welltower (WELL)
- Ventas (VTR)
- Healthpeak Properties
- Omega Healthcare Investors (OHI)
- CareTrust REIT (CTRE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SBRA vs…
SABRA HEALTH CARE REIT INC is found in…
Frequently asked questions
What does SABRA HEALTH CARE REIT INC (SBRA) do?
Sabra Health Care REIT, Inc. is a real estate investment trust that owns and invests in a portfolio of real estate assets within the healthcare sector. The company primarily focuses on skilled nursing and transitional care facilities, as well as senior housing communities. It operates through property investments and manages a portfolio of healthcare-related properties across the United States.
What sector is SABRA HEALTH CARE REIT INC (SBRA) in?
SABRA HEALTH CARE REIT INC (SBRA) is classified in the Real Estate sector. Its industry is healthcare REITs. It trades on NASDAQ.
Does SBRA pay a dividend?
Yes — SABRA HEALTH CARE REIT INC (SBRA) pays a dividend, with an indicated yield of about 8.27% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are SABRA HEALTH CARE REIT INC's (SBRA) competitors?
Notable peers of SABRA HEALTH CARE REIT INC (SBRA) include Welltower, Ventas, Healthpeak Properties, Omega Healthcare Investors and CareTrust REIT. This peer set is informational only — not financial advice.
Is SABRA HEALTH CARE REIT INC (SBRA) overbought or oversold right now?
SABRA HEALTH CARE REIT INC (SBRA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 48, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SBRA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.